Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SATURN trial of sphenopalatine block for headache after non-traumatic subarachnoid hemorrhage
2024-514282-19-00Phase 2Authorised
- Sponsor
- CHU Grenoble Alpes
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lidocaine in subarachnoid hemorrhage (SAH) (2 arms), sponsored by CHU Grenoble Alpes. Primary endpoint: Total morphine consumption over 72 hours. Planned start May 2025; status: authorised.
02
Drugs
lidocaine
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2024-514282-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514282-19-00.